down arrow

Achieve Life Sciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0044685008
USD
4.78
0.23 (5.05%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.705.18

52 Week

1.845.78
Valuation
Technical
Day's Volume

CASH

1.53 M

Shareholding (Mar 2025)

FII

6.15%

Held by 17 FIIs

DII

74.27%

Held by 17 DIIs

Promoter

4.52%

How big is Achieve Life Sciences, Inc.?

22-Jun-2025

As of Jun 18, Achieve Life Sciences, Inc. has a market capitalization of 103.36 million, with net sales of 0.00 million and a net profit of -46.16 million over the last four quarters. The company reported shareholder's funds of 20.90 million and total assets of 38.63 million as of Dec 24.

Market Cap: As of Jun 18, Achieve Life Sciences, Inc. has a market capitalization of 103.36 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Achieve Life Sciences reported net sales of 0.00 million and a net profit of -46.16 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 20.90 million and total assets of 38.63 million.

Read More

What does Achieve Life Sciences, Inc. do?

22-Jun-2025

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company focused on developing cytisine for smoking cessation. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $103.36 million.

Overview: <BR>Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 103.36 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.30 <BR>Return on Equity: -439.90% <BR>Price to Book: 10.06<BR><BR>Contact Details: <BR>Address: 520 Pike St Ste 2250, SEATTLE WA : 98101-4013 <BR>Tel: ['1 425 6861500', '1 415 3753340'] <BR>Fax: 1 302 6365454 <BR>Website: http://achievelifesciences.com/

Read More

Who are in the management team of Achieve Life Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Achieve Life Sciences, Inc. includes Executive Chairman Richard Stewart, CEO John Bencich, Directors Scott Cormack, Donald Joseph, Martin Mattingly, Jay Moyes, and Independent Director H. Stewart Parker, who oversee the company's strategic direction and operations.

As of March 2022, the management team of Achieve Life Sciences, Inc. includes the following individuals:<BR><BR>- Mr. Richard Stewart, who serves as the Executive Chairman of the Board.<BR>- Mr. John Bencich, who is the Chief Executive Officer, Principal Executive Officer, and a Director.<BR>- Mr. Scott Cormack, who is a Director.<BR>- Mr. Donald Joseph, who is an Independent Director.<BR>- Dr. Martin Mattingly, who is also an Independent Director.<BR>- Mr. Jay Moyes, who serves as an Independent Director.<BR>- Ms. H. Stewart Parker, who is an Independent Director.<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Achieve Life Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of July 31, 2017, Achieve Life Sciences, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics and a 1-year stock return of -22.74%, significantly underperforming the S&P 500.

As of 31 July 2017, the valuation grade for Achieve Life Sciences, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 12.92, and an EV to EBITDA of -2.61. <BR><BR>In comparison to its peers, Achieve Life Sciences shows a less favorable position; for instance, Abeona Therapeutics, Inc. has an EV to EBITDA of -3.6927, while MediWound Ltd. has a more severe EV to EBITDA of -9.0843. The company's return metrics also reflect its struggles, with a 1-year stock return of -22.74% compared to a 10.26% return for the S&P 500, highlighting its underperformance in the market. Overall, the combination of poor ratios and negative returns suggests that Achieve Life Sciences, Inc. is overvalued in its current state.

Read More

Is Achieve Life Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Achieve Life Sciences, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

As of 21 August 2025, the technical trend for Achieve Life Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the daily moving averages indicate a mildly bearish stance, and the Bollinger Bands show a mixed signal with weekly mildly bullish and monthly bearish readings. The RSI does not provide any clear signal on either time frame. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -18.47% versus the S&P 500's 12.22%, and a one-year return of -34.77% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish with mixed indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 150 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-118.64%

stock-summary
Price to Book

3.59

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
67.13%
0%
67.13%
6 Months
13.54%
0%
13.54%
1 Year
4.82%
0%
4.82%
2 Years
-18.15%
0%
-18.15%
3 Years
73.82%
0%
73.82%
4 Years
-31.42%
0%
-31.42%
5 Years
-33.47%
0%
-33.47%

Achieve Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Achieve Life Sciences, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Achieve Life Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the daily moving averages indicate a mildly bearish stance, and the Bollinger Bands show a mixed signal with weekly mildly bullish and monthly bearish readings. The RSI does not provide any clear signal on either time frame. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -18.47% versus the S&P 500's 12.22%, and a one-year return of -34.77% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish with mixed indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-212.43%
EBIT to Interest (avg)
-19.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.30
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
50.15%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
12.92
EV to EBIT
-2.60
EV to EBITDA
-2.61
EV to Capital Employed
-39.08
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-439.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 14 Schemes (15.06%)

Foreign Institutions

Held by 17 Foreign Institutions (6.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -49.41% vs -3.66% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.50",
          "val2": "-8.40",
          "chgp": "-48.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.80",
          "chgp": "-75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.70",
          "val2": "-8.50",
          "chgp": "-49.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.56% vs 29.72% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.80",
          "val2": "-27.00",
          "chgp": "-43.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "2.90",
          "chgp": "-24.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.80",
          "val2": "-29.80",
          "chgp": "-33.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.50
-8.40
-48.81%
Interest
0.20
0.80
-75.00%
Exceptional Items
-0.10
-0.10
Consolidate Net Profit
-12.70
-8.50
-49.41%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -49.41% vs -3.66% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-38.80
-27.00
-43.70%
Interest
2.20
2.90
-24.14%
Exceptional Items
-0.90
-0.50
-80.00%
Consolidate Net Profit
-39.80
-29.80
-33.56%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.56% vs 29.72% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Achieve Life Sciences, Inc. stock-summary
stock-summary
Achieve Life Sciences, Inc.
Pharmaceuticals & Biotechnology
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
Company Coordinates stock-summary
Company Details
520 Pike St Ste 2250 , SEATTLE WA : 98101-4013
stock-summary
Tel: 1 425 68615001 415 3753340
stock-summary
http://achievelifesciences.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."